18,090 Shares in Cencora, Inc. (NYSE:COR) Bought by World Investment Advisors LLC

World Investment Advisors LLC acquired a new stake in shares of Cencora, Inc. (NYSE:CORFree Report) in the 3rd quarter, Holdings Channel.com reports. The fund acquired 18,090 shares of the company’s stock, valued at approximately $4,072,000.

A number of other hedge funds have also recently modified their holdings of COR. New Millennium Group LLC purchased a new position in Cencora during the second quarter valued at $26,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the second quarter worth $30,000. Concord Wealth Partners bought a new position in shares of Cencora during the third quarter valued at $30,000. SYSTM Wealth Solutions LLC purchased a new position in shares of Cencora in the 2nd quarter worth about $36,000. Finally, Ashton Thomas Securities LLC bought a new position in Cencora in the 3rd quarter worth about $41,000. Institutional investors own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This represents a 7.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 93,018 shares of company stock valued at $22,478,942. Insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on COR shares. Bank of America restated a “neutral” rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Wells Fargo & Company reduced their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a report on Friday. Finally, Barclays boosted their price target on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $275.60.

Check Out Our Latest Research Report on COR

Cencora Price Performance

NYSE COR opened at $232.24 on Friday. The stock has a market capitalization of $44.89 billion, a price-to-earnings ratio of 30.92, a PEG ratio of 1.54 and a beta of 0.45. Cencora, Inc. has a 1-year low of $195.83 and a 1-year high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The business’s fifty day moving average price is $238.36 and its 200-day moving average price is $233.91.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.95%. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio (DPR) is presently 29.29%.

About Cencora

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Featured Articles

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.